Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2023 | The impact of symptoms on QoL in patients with MPNs

Marina Kremyanskaya • 10 Jun 2023
EHA 2023
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases

Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York City, NY, discusses the impact of symptoms on the quality of life (QoL) of patients with myeloproliferative neoplasms (MPNs), highlighting the need to develop therapies and supportive care for symptom control. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultant to Protagonist, Abbvie, CTI, Morphosys

More from Marina Kremyanskaya

Combination strategies under investigation in myelofibrosis and their use in the frontline setting 1:57
Combination strategies under investigation in myelofibrosis and their use in the frontline setting
Marina Kremyanskaya • 17 Jun 2025
The evolution of treatment options for myelofibrosis: newly available JAK inhibitors and beyond 2:31
The evolution of treatment options for myelofibrosis: newly available JAK inhibitors and beyond
Marina Kremyanskaya • 17 Jun 2025
Early findings from the Phase I/II SANRECO study: divesiran in polycythemia vera 4:08
Early findings from the Phase I/II SANRECO study: divesiran in polycythemia vera
Marina Kremyanskaya • 17 Jun 2025
The evolving treatment landscape for patients with polycythemia vera 3:37
The evolving treatment landscape for patients with polycythemia vera
Marina Kremyanskaya • 9 Dec 2024

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals